TABLE 3.
Summary of TiLV vaccines and their efficacy
| Vaccine type | Description | Country of origin | Dose (TCID50 fish−1) | Administration route | Adjuvant | % RPS or survival rate | Reference |
|---|---|---|---|---|---|---|---|
| Live attenuated | 17 and 20 passages (P17 & P20) on cell culture | Israel | 1.2 × 107 (P17) and 8.9 × 106 (P20) | IP | No | >50 a | Bacharach and Eldar (2016) |
| DNA vaccine | Segment 8 (VP20) | China | 5 µg | IM | No | 50 b | Zeng, Wang, Chen, et al. (2021) |
| Recombinant vaccine | 20 µg | IM | M402 (China) | 52.5 b | |||
| DNA +recombinant vaccine | 5 µg of DNA vaccine (prime) + 20 µg of recombinant vaccine (booster) | IM | M402 for booster | 72.5 b | |||
| Inactivated | β‐propiolactone | China | 105; 106; 107 | IM | Montanide IMS 1312 VG (Seppic) | 32.1 a –85.7 a | Zeng, Wang, Hu, et al. (2021) |
| IM | No | 14.3 a –42.9 a | |||||
| Heat | Thailand | 1.8 × 106 | IP | No | 71.3 a | This study | |
| Formalin | 1.8 × 106 | IP | No | 79.6 a |
IM, intramuscular injection; IP, intraperitoneal injection.
a
RPS, Relative percentage survival.
b
Survival rate.